Evidence map›Paper›PMID 29338452›Full record

ReviewExpert review of molecular diagnostics2018

An update on diagnostic and prognostic biomarkers for traumatic brain injury.

Kevin K Wang, Zhihui Yang, Tian Zhu, Yuan Shi, Richard Rubenstein, J Adrian Tyndall, Geoff T Manley

3 registry-linked trialsAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Expert review of molecular diagnostics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 296 papers, 17 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
296citing papers in PubMed, 17 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05000320 withdrawnnot on this mapstarted 2023, after this paper: background citation

VIGAB-BIOSTAT: Neuronal Injury Panel Substudy

TypeobservationalSponsorUniversity of FloridaRan2023 to 2024Enrolled0ConditionsStatus Epilepticus, Cardiac Arrest With Successful ResuscitationArmsNeuronal Injury Panel
NCT06282965 phase1 / phase2recruitingnot on this mapstarted 2024, after this paper: background citation

A Randomized, Double-blind, Placebo Controlled Study of the Safety and Efficacy of Angiotensin (1-7) in Persons With Moderate to Severe Traumatic Brain Injury (TBI)

TypeinterventionalSponsorUniversity of ArizonaRan2024 to 2027Enrolled90ConditionsTraumatic Brain InjuryArmsAngiotensin (1-7), Sterile saline
NCT07397091 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

ROUTINE INFLAMMATORY AND METABOLIC BIOMARKERS. Can They Predict a Positive Head CT in Paediatric Minor Traumatic Brain Injury?

TypeobservationalSponsorIuliu Hatieganu University of Medicine and PharmacyRan2026 to 2026Enrolled800ConditionsBrain Injury Traumatic Mild
3 · Its place in the literature

Who cites it

296 citing papers in PubMed, 17 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. The diagnostic and prognostic value of glial fibrillary acidic protein in traumatic brain injury: a systematic review and meta-analysis.European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2023
    Pooled it
  13. The role of spectrin breakdown products in patients with traumatic brain injury: a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023
    Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Trial
  19. Article
  20. Article

236 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kevin K Wanga Program for Neurotrauma, Neuroproteomics & Biomarkers Research, Departments of Emergency Medicine, Psychiatry, Neuroscience and Chemistry , University of Florida , Gainesville , Florida , USA.ORCID 0000-0002-9343-6473
Zhihui Yanga Program for Neurotrauma, Neuroproteomics & Biomarkers Research, Departments of Emergency Medicine, Psychiatry, Neuroscience and Chemistry , University of Florida , Gainesville , Florida , USA.
Tian Zhua Program for Neurotrauma, Neuroproteomics & Biomarkers Research, Departments of Emergency Medicine, Psychiatry, Neuroscience and Chemistry , University of Florida , Gainesville , Florida , USA.
Yuan Shib Department Of Pediatrics, Daping Hospital, Chongqing , Third Military Medical University , Chongqing , China.
Richard Rubensteinc Laboratory of Neurodegenerative Diseases and CNS Biomarker Discovery, Departments of Neurology and Physiology/Pharmacology , SUNY Downstate Medical Center , Brooklyn , NY , USA.
J Adrian Tyndalld Department of Emergency Medicine , University of Florida , Gainesville , Florida , USA.
Geoff T Manleye Brain and Spinal Injury Center , San Francisco General Hospital , San Francisco , CA , USA.

Funding

Transforming Research and Clinical Knowledge in Traumatic Brain InjuryU01NS086090 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DIAZ-ARRASTIA, RAMON, GIACINO, JOSEPH THOMAS · 2013 to 2017
$19.1M
Transforming Traumatic Brain Injury Research and Clinical CareRC2NS069409 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MANLEY, GEOFFREY T · 2009 to 2011
$4.3M
Elucidate Consequences of Autoimmune Response to Protease-modified GFAP in TBIR21NS085455 · NINDS · UNIVERSITY OF FLORIDA · PI WANG, KEVIN KA WANG · 2014 to 2015
$397k
Repetitive mTBI-induced neurobehavioral changes and CTE-like proteinopathyI01RX001859 · VA · VETERANS HEALTH ADMINISTRATION · PI WANG, KEVIN KA WANG · 2016 to 2020
–
NINDS NIH HHS R21 NS085455NINDS NIH HHS RC2 NS069409NINDS NIH HHS U01 NS086090RRD VA I01 RX001859
6 · The paper itself

Abstract

introductionTraumatic brain injury (TBI) is a major worldwide neurological disorder of epidemic proportions. To date, there are still no FDA-approved therapies to treat any forms of TBI. Encouragingly, there are emerging data showing that biofluid-based TBI biomarker tests have the potential to diagnose the presence of TBI of different severities including concussion, and to predict outcome. Areas covered: The authors provide an update on the current knowledge of TBI biomarkers, including protein biomarkers for neuronal cell body injury (UCH-L1, NSE), astroglial injury (GFAP, S100B), neuronal cell death (αII-spectrin breakdown products), axonal injury (NF proteins), white matter injury (MBP), post-injury neurodegeneration (total Tau and phospho-Tau), post-injury autoimmune response (brain antigen-targeting autoantibodies), and other emerging non-protein biomarkers. The authors discuss biomarker evidence in TBI diagnosis, outcome prognosis and possible identification of post-TBI neurodegernative diseases (e.g. chronic traumatic encephalopathy and Alzheimer's disease), and as theranostic tools in pre-clinical and clinical settings. Expert commentary: A spectrum of biomarkers is now at or near the stage of formal clinical validation of their diagnostic and prognostic utilities in the management of TBI of varied severities including concussions. TBI biomarkers could serve as a theranostic tool in facilitating drug development and treatment monitoring.

Indexed as

BiomarkersBrain Injuries, TraumaticHumansLiquid BiopsyNeuroimagingPrognosisSeverity of Illness IndexBiomarkersBiomarkersdiagnosticsneurotraumatheranosticstraumatic brain injury

Identifiers

PMID29338452
PMCPMC6359936

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.